Therma Fisher Acquires Rapid COVID-19 Test Provider Mesa Biotech for $450M
What You Should Know:
– has entered into a definitive agreement to
a San Diego,
CA-based molecular diagnostic company, for approximately $450 million in cash.
Under the terms of the agreement, Thermo Fisher will pay up to an additional
$100 million in cash upon the completion of certain milestones following the
close of the transaction.
– Mesa Biotech designs, develops, manufactures, and commercializes next generation Rapid PCR tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care (POC).
– Mesa Biotech’s Accula™ SARS-CoV-2 test was among the first
POC tests to obtain Emergency Use Authorization, providing results within 30
minutes, with higher accuracy than other rapid tests on the market.
– The company has approximately 500 employees and reported
$45M in revenue in 2020.